13 Notes The above financial summary may not be comparable across the periods presented due to the changes in the Group structure. For changes in the accounting policies, adoption of new and/or revised accounting standards, as well as changes in presentation of financial statements for the current financial year, only the comparative figures for the previous year are restated to conform with the requirements arising from the said changes or adoption. Comparative figures for the previous year are restated, where applicable, upon the completion of the Purchase Price Allocation on the Group’s acquisitions of subsidiaries as required under MFRS 3, Business Combinations. 1. Labs comprise the Group’s diagnostic laboratory business. In the table above, prior to FY2022, Labs was classified as part of Malaysia, Singapore, India and Türkiye and Europe healthcare services. 2. Others comprise mainly corporate offices as well as other investment holding entities. 3. Arises from the application of MFRS 129, Financial Reporting in Hyperinflationary Economies for component entities whose functional currency is the Turkish Lira. 4. Being earnings before interest, tax, depreciation, amortisation, exchange differences, share of results of associates and joint ventures and other non-operational items. 5. Being net assets attributable to ordinary shareholders (excluding non-controlling interests). 6. Being net assets attributable to ordinary shareholders (excluding non-controlling interests) less goodwill and intangible assets. 7. Being PATMI for the year over average of equity attributable to owners of the Company as at year-end and beginning of the year. 8. Debt includes loans and borrowings as well as lease liabilities and bank overdrafts. FY2020 FY2021 FY2022 FY2023 FY2024 A. Income Statement (RM Million) Revenue by Strategic Business Units Singapore 3,887 5,033 4,913 5,573 6,131 Malaysia 2,187 2,727 3,074 3,684 4,154 India 2,656 3,729 3,175 3,555 4,028 Greater China 662 877 998 1,307 1,529 Türkiye and Europe 3,462 4,347 4,455 5,943 7,238 Southeast Asia 138 – – – – Hospital and Healthcare 12,992 16,713 16,615 20,062 23,080 IMU Health 249 258 261 54 – Labs total revenue – – 1,662 1,665 1,779 Less: Labs inter-segment revenue – – (603) (685) (747) Labs1 – – 1,059 980 1,032 Others2 9 8 5 6 7 13,250 16,979 17,940 21,102 24,119 PLife REIT total revenue 367 371 376 408 414 Less: PLife REIT inter-segment revenue (212) (218) (227) (255) (266) PLife REIT 155 153 149 153 148 13,405 17,132 18,089 21,255 24,267 Hyperinflationary adjustment3 – – (101) (320) 116 Total 13,405 17,132 17,988 20,935 24,383 EBITDA4 by Strategic Business Units Singapore 1,359 1,693 1,484 1,627 1,825 Malaysia 556 760 847 937 1,060 India 201 665 492 600 723 Greater China (147) (70) (60) 75 145 Türkiye and Europe 796 1,199 1,058 1,249 1,489 Southeast Asia 46 – – (2) (2) Hospital and Healthcare 2,811 4,247 3,821 4,486 5,240 IMU Health 76 87 85 13 – Labs1 – – 369 345 375 Others2 (107) (186) (171) (121) (159) Eliminations – – 9 – (1) 2,780 4,148 4,113 4,723 5,455 PLife REIT 309 350 278 326 291 Eliminations (212) (218) (234) (262) (276) 2,877 4,280 4,157 4,787 5,470 Hyperinflationary adjustment3 – – (106) (141) (31) Total 2,877 4,280 4,051 4,646 5,439 Profit After Tax and Minority Interest (“PATMI”) Including Exceptional Items 289 1,863 1,548 2,952 2,657 Excluding Exceptional Items 715 1,595 1,381 1,280 1,685 B. Financial Position (RM Million) Total Assets 44,534 45,510 48,467 50,192 56,759 Net Borrowings 7,441 5,856 7,170 7,672 13,270 Equity attributable to Owners of the Company 21,740 22,425 26,192 29,106 30,140 C. Financial Ratios Basic Earnings per Share (sen) Including Exceptional Items 2.27 20.20 17.00 33.52 30.17 Excluding Exceptional Items 7.13 17.15 15.09 14.53 19.13 Net Assets5 per Share (RM) 2.48 2.55 2.97 3.30 3.42 Net Tangible Assets6 per Share (RM) 0.87 0.94 1.16 1.35 1.16 Return on Equity7 (%) Including Exceptional Items 1.3% 8.4% 6.5% 10.7% 9.0% Excluding Exceptional Items 3.2% 7.2% 5.8% 4.6% 5.7% Return on Total Assets (%) Including Exceptional Items 0.6% 4.1% 3.2% 5.9% 4.7% Excluding Exceptional Items 1.6% 3.5% 2.8% 2.5% 3.0% Net Debt Equity Ratio8 (times) 0.28 0.21 0.25 0.24 0.39
RkJQdWJsaXNoZXIy NDgzMzc=